Multiple Australian outlets report the case of “Aaron”, who loses three fingertips due to severe eczema and related complications. The articles say an injection therapy—described as potentially able to prevent or reduce such outcomes—was recommended for children aged six to 11 in March 2022. However, the reports state that eligible children are still waiting for access to the treatment. The coverage emphasizes the gap between the initial recommendation for the age group and the availability of the injection in practice. While details of Aaron’s broader medical course are presented through the individual account, the central common thread across the outlets is that delays in implementation are affecting children who could benefit from the medication. The reporting focuses on how the lack of timely access can result in serious harm, using Aaron’s experience as a reference point for the wider issue affecting other families. The articles call attention to the continuing waiting period for the recommended injection therapy for children within the specified age range.